Ederlyn Q. Dia

TL;DR: Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors, and effects of the molecular abnormalities in vitro are identified.

TL;DR: Combined EGFR/mTOR kinase inhibition inhibits tumor cell growth and has an additive effect on inhibiting downstream PI3K pathway signaling and combination therapy provides added benefit in promoting cell death in PTEN-deficient tumor cells.

TL;DR: Large-scale expression analyses were used to identify glioblastoma-associated genes (GAG) that are associated with a more malignant phenotype via comparison with lower-grade astrocytomas and highlight that the development of gene pathway-targeted therapies may need to be specifically tailored to each subtype of gliOBlastoma.

TL;DR: The presence and purification of two naturally occurring forms of PTN (18 and 15 kDa) that differentially promote glioblastoma migration and proliferation are reported on, indicating that thePTN18-PTPRZ1 and the PTN15-ALK signaling pathways represent potentially important therapeutic targets for glioblasts invasion and growth.